Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Study Identifier:
ALXN1210-aHUS-312
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Aug 2017 - Dec 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Ravulizumab
Date
Aug 2017 - Dec 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The purpose of the study is to assess the efficacy of ravulizumab to control disease activity in children and adolescents with aHUS who have not previously used a complement inhibitor (complement inhibitor treatment-naïve), as well as in complement inhibitor-experienced (eculizumab-experienced) adolescent participants.
Trial Locations
Location
Status
Location
Research Site
Hollywood, Florida, United States, 33021
Status
N/A
Location
Research Site
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Research Site
Detroit, Michigan, United States, 48201
Status
N/A
Location
Research Site
Omaha, Nebraska, United States, 68198
Status
N/A
Location
Research Site
Hackensack, New Jersey, United States, 07601
Status
N/A
Location
Research Site
Charlotte, North Carolina, United States, 28203
Status
N/A